Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention
According to the research by Christmas 2026 almost a 3rd of UK households will have someone using or considering using GLP-1, leading to big changes in the choices consumers make, particularly in light of Grocery
This opens doors for patients who may not have coverage for weight loss treatments or those who prefer to manage their healthcare costs directly
Saxenda is an injectable medication containing liraglutide
One of the key reasons patient advocates cite for preferring GLP-1 therapies, beyond clinical benefits, is their convenienceas these drugs are administered once weekly, unlike insulin, which requires daily injections